Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Elisei

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
The Journal of Clinical Endocrinology and Metabolism|January 16, 2015
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution studyD Viola, G Materazzi, L Valerio, et al.
Endocrine-Related Cancer|May 27, 2006
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literatureL Fugazzola, E Puxeddu, N Avenia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinomaM Schlumberger, R Elisei, S Müller, et al.
Journal of Endocrinological Investigation|May 6, 2018
Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societiesF Pacini, F Basolo, R Bellantone, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2019
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in ItalyL D Locati, A Piovesan, C Durante, et al.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2009
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawalR Elisei, M Schlumberger, A Driedger, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled studyF Pacini, P W Ladenson, M Schlumberger, et al.
Journal of Endocrinological Investigation|January 18, 2021
Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern ItalyL Dal Maso, C Panato, A De Paoli, et al.
Journal of Endocrinological Investigation|July 22, 2019
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter studyP Premoli, M L Tanda, E Piantanida, et al.
Journal of Endocrinological Investigation|August 10, 2023
Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patientsZ M Besharat, S Trocchianesi, A Verrienti, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
The Journal of Clinical Endocrinology and Metabolism|January 16, 2015
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution studyD Viola, G Materazzi, L Valerio, et al.
Endocrine-Related Cancer|May 27, 2006
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literatureL Fugazzola, E Puxeddu, N Avenia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinomaM Schlumberger, R Elisei, S Müller, et al.
Journal of Endocrinological Investigation|May 6, 2018
Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societiesF Pacini, F Basolo, R Bellantone, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2019
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in ItalyL D Locati, A Piovesan, C Durante, et al.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2009
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawalR Elisei, M Schlumberger, A Driedger, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled studyF Pacini, P W Ladenson, M Schlumberger, et al.
Journal of Endocrinological Investigation|January 18, 2021
Trends in thyroid function testing, neck ultrasound, thyroid fine needle aspiration, and thyroidectomies in North-eastern ItalyL Dal Maso, C Panato, A De Paoli, et al.
Journal of Endocrinological Investigation|July 22, 2019
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter studyP Premoli, M L Tanda, E Piantanida, et al.
Journal of Endocrinological Investigation|August 10, 2023
Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patientsZ M Besharat, S Trocchianesi, A Verrienti, et al.
Pageof 11